{"id":2562,"date":"2022-10-04T13:40:49","date_gmt":"2022-10-04T13:40:49","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/?page_id=2562"},"modified":"2026-04-28T17:15:43","modified_gmt":"2026-04-28T17:15:43","slug":"leadership","status":"publish","type":"page","link":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/leadership\/","title":{"rendered":"Leadership"},"content":{"rendered":"
<\/div><\/div><\/div>

Leadership<\/strong><\/h1>\n<\/div><\/div>

Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value.<\/p>\n<\/div><\/div><\/div><\/div>

Management Team<\/h3>\n<\/div><\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Jennifer Good<\/h4>\n

Co-Founder,
\nPresident and CEO<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Thomas Sciascia, M.D.<\/h4>\n

Co-Founder,
Chief Scientific Officer<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

David Clark, MBChB, MRCP<\/h4>\n

Chief Medical Officer<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Lisa Delfini<\/h4>\n

Chief Financial Officer<\/p>\n<\/div><\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Farrell Simon, Pharm.D.<\/h4>\n

Chief Commercial Officer<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Danine Summers<\/h4>\n

VP, Medical Affairs<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Katherine Takaki, Ph.D.<\/h4>\n

VP, Global Regulatory Affairs<\/p>\n<\/div><\/div><\/div>

\"\"<\/a><\/h1>\n

Paula Buckley<\/h4>\n

VP, Clinical Operations<\/p>\n<\/div><\/div><\/div><\/div>

Board of Directors<\/h3>\n<\/div><\/div>
David Meeker, M.D. \u2013 Chairman<\/h5>

David Meeker, M.D. has served as a member of our board of directors and our chairman since July 2017. Dr. Meeker has served as Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals, a biopharmaceutical company, since July 2020. Prior to joining Rhythm Pharmaceuticals, Dr. Meeker was Chief Executive Officer and director of KSQ Therapeutics, Inc., from September 2017 to July 2020 and worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including President and Chief Executive Officer of Genzyme, a Sanofi Company from October 2011 until January 2016, as a member of Sanofi\u2019s Executive Committee from 2012 to June 2017 and as Executive Vice President and head of Sanofi Genzyme, Sanofi\u2019s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as Chief Operating Officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of medicine at Ohio State University. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since November 2015 and as its chairman of the board since April 2017. He has served as Chairman of Pharvaris, a publicly traded company, since January 2021 . Dr. Meeker has also served as a director of MyoKardia, Inc., a publicly traded biopharmaceutical company, from June 2017 to December 2020. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. He completed his internal medicine training at Harvard University\u2019s Beth Israel Hospital and pulmonary\/critical care training at Boston University. <\/p>\n<\/div><\/div>

James Cassella, Ph.D.<\/h5>

James Cassella, Ph.D. has served as a member of our board of directors since February 2020. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc., a publicly-traded biotechnology company, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.<\/p>\n<\/div><\/div>

Dominick Colangelo<\/h5>

Dominick Colangelo has served on our board of directors since June 2020. Mr. Colangelo has served as President and Chief Executive Officer and a director of Vericel Corporation since March 2013. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly\u2019s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. in Accounting from the State University of New York at Buffalo and a J.D. from the Duke University School of Law.<\/p>\n<\/div><\/div>

Jennifer Good<\/h5>

Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, a publicly-traded biopharmaceutical company, since June 2019. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreich\u2019s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich\u2019s Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. <\/p>\n<\/div><\/div>

Michael Heffernan<\/h5>

Michael Heffernan has served on our board of directors since February 2017. Mr. Heffernan served as the President, Chief Executive Officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its President and Chief Executive Officer from 2005 to 2010. Mr. Heffernan previously founded and served as President and Chief Executive Officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., from 1994 to 1999, and subsequently served as President and Chief Executive Officer of PhyMatrix from 1999 to 2002. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. Mr. Heffernan has served on the board of directors of Akebia Therapeutics, a publicly traded biopharmaceutical company, since December 2018, Biohaven Pharmaceuticals, a publicly traded biopharmaceutical company, since January 2020 and Synlogic, Inc, a publicly traded company since December 2020. Mr. Heffernan served on the board of directors of Veloxis Pharmaceuticals A\/S, a specialty pharmaceutical company that is publicly traded on Nasdaq OMX Copenhagen, from April 2015 until February 2020, and served as its chairman from April 2016 until February 2020. Mr. Heffernan also previously served on the board of directors of Keryx Biopharmaceuticals, Inc., a publicly traded pharmaceutical company, from April 2016 until December 2018, and on the board of directors of Ocata Therapeutics, Inc., a publicly traded biotechnology company, from April 2012 to February 2016, and has served on the board of several privately held companies. Mr. Heffernan graduated from the University of Connecticut with a B.S. in pharmacy in 1987 and is a registered pharmacist. <\/p>\n<\/div><\/div>

Ed Mathers<\/h5>

Edward Mathers has served on our board of directors since July 2017. Mr. Mathers has been a partner at New Enterprise Associates, Inc., a private venture capital firm, since August 2008. Mr. Mathers has served as a director of multiple publicly traded biopharmaceutical companies including ObsEva SA, since November 2015, Rhythm Pharmaceuticals Inc., since March 2013, Synlogic, Inc., since October 2012, Inozyme Pharma, Inc. since January 2017 and Mirum Pharmaceuticals, Inc. since November 2018. Mr. Mathers has also served on the board of directors at Akouos, Inc., a publicly traded biotechnology company, since October 2017. He previously served as a director of Liquidia Technologies, Inc., a publicly traded biopharmaceutical company, from April 2009 until May 2019, and as a director of Ra Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from February 2010 until April 2020. He is also on the board of a number of private life sciences companies. Mr. Mathers earned his B.S. in chemistry from North Carolina State University. <\/p>\n<\/div><\/div>

Anne VanLent<\/h5>

Anne VanLent has served on our board of directors since October 2018. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company, from 2002 through 2008. From 1997 to 2001, she was the Executive Vice President \u2013 Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly traded biopharmaceutical company that was acquired by Elan Corp. plc. Ms. VanLent has served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, since August 2016. From May 2013 to June 2020, Ms. VanLent also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.), a publicly traded biotechnology company. Ms. VanLent served as a director of Ocera Therapeutics, Inc., a publicly traded biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), a publicly traded biopharmaceutical company, from March 2013 to June 2017; and Onconova Therapeutics, Inc., a publicly traded biopharmaceutical company, from June 2013 to May 2016. Ms. VanLent received a B.A. degree in physics from Mount Holyoke College.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Jennifer Good<\/h4>\n

Co-Founder, President and CEO<\/p>\nJennifer Good is our co-founder and has served as a member of our Board of Directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, a publicly traded biopharmaceutical company, since June 2019. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreich\u2019s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich\u2019s Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Our Board of Directors believes that Ms. Good\u2019s in-depth knowledge of our business from serving as our founder, President and Chief Executive Officer and her perspective and experience as an executive and a director at publicly traded and privately held companies in the life sciences industry, provide her with the qualifications and skills to serve on our Board of Directors.<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Lisa Delfini<\/h4>\n

Chief Financial Officer<\/p>\nLisa Delfini has served as our Chief Financial Officer since August 2021. Ms. Delfini served as a Financial Accounting and Advisory Services Partner at Marcum LLP, an accounting and advisory services company, from 2015 until August 2021, specializing in providing services to companies in the life science and high-tech industries. Previously, she worked at General Electric Company, a multinational conglomerate, as Global Controller for the GE Corporate Technical Center of Excellence from 2011 to 2014 and as Global Controller for the GE Industrial Solutions division from 2014 to 2015. Ms. Delfini began her career at Deloitte & Touche LLP, where she worked for 16 years, completing her time there as a Client Service Partner. Ms. Delfini received a B.S. in accounting from Lehigh University and is a Certified Public Accountant licensed by the state of Connecticut.<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

David Clark, MBChB, MRCP<\/h4>\n

Chief Medical Officer<\/p>\n

David Clark, MBChB, MRCP\u00a0has served as our Chief Medical Officer since November 2022. Prior to joining us, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, Inc., a biopharmaceutical company, from November 2020 to September 2022, leading the company\u2019s clinical development, regulatory and medical affairs teams. Prior to that, he served as Chief Medical Officer for Aldeyra Therapeutics, Inc., a biotechnology company, from January 2016 to May 2020.\u00a0 He has also served as Chief Medical Officer for Wilson Therapeutics and NormOxys, Inc. and held senior leadership positions at TransTech Pharma, Pfizer Inc., and GlaxoSmithKline, formerly known as Smithkline Beecham. Dr. Clark holds a Bachelor of Medicine and Surgery (MBChB) from the University of Edinburgh Medical School and is admitted to Membership of the Royal College of Physicians (MRCP). Dr. Clark also completed a research fellowship in respiratory medicine in the United Kingdom.<\/p><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Thomas Sciascia, M.D.<\/h4>\n

Co-Founder, Chief Scientific Officer<\/p>\nThomas Sciascia, M.D., is our co-founder and has served as our Chief Scientific Officer since November 2022. Prior to that, he served as our Chief Medical Officer from our inception, in March 2011, until November 2022. Previously, Dr. Sciascia was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. from 1997 to 2000 as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc) from 2000 to 2001. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Farrell Simon, Pharm.D.<\/h4>\n

Chief Commerical Officer<\/p>\n

Farrell Simon, Pharm.D.\u00a0has served as our Chief Commercial Officer since February 2023.\u00a0 Prior to that, he served as our Senior Vice President, Head of Commercial and Strategy, from February 2022 until February 2023 and Vice President, Head of US Marketing, from September 2020 until February 2022. Previously, Dr. Simon was the Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc. and a member of the biopharma executive leadership team from January 2018 to September 2020. Prior to joining Pfizer, Dr. Simon gained general management, marketing, and medical affairs experience at Procter & Gamble.\u00a0 Dr. Simon is the founder and Chief Executive Officer of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the business school and the College of Pharmacy at the University of Florida. Dr. Simon holds both an M.B.A. and a Pharm.D. from the University of Florida.<\/p><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Danine Summers<\/h4>\n

VP, Medical Affairs<\/p>\n

Danine Summers is our Vice President of Medical Affairs at Trevi. Danine has over 35 years of experience in the pharmaceutical industry, the last 20 years in dermatology and more recently in pulmonology.\u00a0 She started her career in field sales with Merck Sharp & Dohme and then moved on to American Scientific Products and Roche Labs. While at Roche Danine completed her MBA and transitioned from sales to marketing. She has 18 years of experience in various areas of Marketing including time with FCB Healthcare (clients included Syntex, Gilead, Allergan and Neutrogena) and Connetics Pharmaceuticals, where she built out the marketing department for the company.\u00a0 For the past 15 years Danine has focused on building the Medical Affairs function in companies where it did not previously exist. This included work done at Medicis, Anacor Pharmeceuticals and Menlo Therapeutics. Further, she has led and\/or participated in over 10 product launches in her career. Danine joined Trevi Therapeutics in early 2020.<\/p><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Katherine Takaki, Ph.D.<\/h4>\n

VP, Global Regulatory Affairs<\/p>\n

Katherine Takaki, Ph.D. is the VP of Global Regulatory Affairs at Trevi. She has over 30 years of pharmaceutical industry experience in regulatory strategy, global project and team management, and drug discovery. Before joining Trevi, Katherine served as Vice President, Global Regulatory Affairs at Iterum Therapeutics where she helped build out the regulatory group to support the Company\u2019s regulatory strategy and operations. Prior to that,\u00a0she held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas and covering all stages of drug discovery and development. She was the global project manager for the team that developed Baraclude for the treatment of hepatitis B and launched it in markets worldwide. She was subsequently the Group Director, Head of Regulatory Strategy Marketed Products at Bristol Myers Squibb. Katherine holds a Ph.D. in Organic Chemistry from the\u00a0Massachusetts Institute of Technology\u00a0and a B.S. in Chemistry from the\u00a0University of Hawaii\u00a0at\u00a0Manoa.<\/p><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t

Paula Buckley<\/h4>\n

VP, Clinical Operations\u00a0<\/p>\n

Paula Buckley is the VP of Clinical Operations at Trevi.\u00a0 She has almost 35 years pharmaceutical industry experience in Analytical Chemistry, Quality Assurance and Clinical Operations.\u00a0 Before joining Trevi Paula served as VP Quality Assurance\/Control at Penwest, as well as several leadership roles in Quality Assurance and Control in companies such as Bayer, Anesiva and I-Health.\u00a0 During her years at Bayer, she worked in leadership roles in Analytical Chemistry in several therapeutic areas.\u00a0 Paula received her Bachelor of Science degree at Southern CT State University in 1987.<\/p><\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":""},"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2562"}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/comments?post=2562"}],"version-history":[{"count":33,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2562\/revisions"}],"predecessor-version":[{"id":3348,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2562\/revisions\/3348"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/media?parent=2562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}